Additio Investment Group

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

Oxford Endovascular is focused on developing an innovative biotechnology device aimed at treating brain aneurysms. The company's technology employs a laser-cut metal alloy that utilizes shape-memory properties, enabling it to be inserted into a patient's brain via a catheter. Once in place, the device expands into a small mesh tube, commonly referred to as a flow diverter, which conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, promoting healing and reducing the risk of rupture. By utilizing advanced engineering techniques, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for individuals affected by this serious condition.

Gedea Biotech AB, founded in 2015 and based in Lund, Sweden, specializes in the development of antibiotic-free treatments for vaginal fungal infections. The company focuses on creating a natural product, GA101, designed to treat and prevent these infections, which affect a significant percentage of women throughout their lives. GA101 functions by lowering the vaginal pH, providing a physical barrier, and inhibiting the formation of biofilms. This innovative approach aims to offer women a safe and effective alternative to traditional antibiotic treatments, promoting better vaginal health without the associated risks of antibiotic use.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.